Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation
Faron again published positive results of the BEXMAB study that focuses on blood cancers. The company seems to have preliminary efficacy proof already in the phase I/II study, which we believe supports the probabilities of the study path being successful. With the positive estimate changes justified by the results we feel that the valuation picture of the share is slightly more neutral, but still not sufficiently attractive in terms of the risk/return ratio.
Login required
This content is only available for logged in users
Faron Pharmaceuticals
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read more on company pageKey Estimate Figures17.04.2023
| 2022 | 23e | 24e | |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| growth-% | |||
| EBIT (adj.) | -27.4 | -15.8 | -3.1 |
| EBIT-% (adj.) | -685,650.00 % | -394,522.50 % | -76,864.00 % |
| EPS (adj.) | -0.48 | -0.25 | -0.05 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | - | - | - |
| EV/EBITDA | - | - | - |
